In both TCGA and CGGA cohorts, tumors with wild-type IDH exhibited higher expression of RIPK1, RIPK3, and MLKL relative to IDH-mutant gliomas (Figs. 1B and S1B), consistent with the more aggressive clinical behavior associated with IDH-wild-type status [27]. This evidence concerns the gene RIPK3 and central nervous system cancer.